Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

GSK said that infectious diseases and HIV represent around two-thirds of GSK’s pipeline, and Brexafemme will slot into its portfolio alongside late-stage antibiotics gepotidacin, vying to become ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...

Gepotidacin, 177Lu-PSMA-617, and durvalumab received FDA approvals, marking significant advancements in urology treatment paradigms. UGN-102's NDA decision for LG-IR-NMIBC is expected by June 13, 2025 ...

GSK Gepotidacin (Blujepa) nabs FDA approval as the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years Structurally Gepotidacin, a triazaacenaphthylene bearing ...

The US Food and Drug Administration (FDA) recently approved Blujepa (gepotidacin), a ground-breaking oral antibiotic for treating uncomplicated urinary tract infections (UTIs). This is the first new ...

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...